Protein binders

#AI / data analytics / healthtech / informatics #Anti-inflammatory #Artificial intelligence (AI) #Cancer research #Covid-19 #EpicentRx #Immunology / Virology & Vaccines #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

New podcast on the significance of drug repurposing

This is the latest episode of the free DDW narrated podcast, titled “Why drug repurposing is so significant for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: AI use in repurposing drugs for Covid-19 and RRx-001: Jack… Read More

#News

#Anti-inflammatory #Cancer research #EpicentRx #Oncology #Polypharmacologic #Precision medicine #Protein binders #Therapeutic targets

RRx-001: Jack of all trades, master of…many

Listen to this article on the DDW podcast: Bryan Oronsky, Chief Development Officer at EpicentRx, discusses how one drug sourced from the defense and aerospace industry, could have many potential disese targets. Introduction The term “dilettante”, at least in English, connotes a sloppy bungler, a smatterer, a second rater, unskilled and… Read More

#Exclusive Content

Man using microscope in lab
#Collaboration #Phenotyping #PhoreMost #Protein binders #Therapeutic targets

PhoreMost enters multi-target collaboration with Arvinas

PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration. Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration… Read More

#Business & Investment #News